Q3 2025 · 13F-HR
Samsara BioCapital, LLCholdings as filed
Filed 2025-11-14 · accession 0001744967-25-000004
$765.9M
Reported value
27
Positions
2025-09-30
Period end
The Brief · Samsara BioCapital, LLC · Q3 2025
AI · grounded in 13F
Samsara BioCapital, LLC established a new position in MLYS valued at $237.5M. The fund also initiated new stakes in SRRK for $209M and KLRS for $66.2M. Additional new positions include SEPN at $59.2M and NGNE at $29.8M. Total assets under management stand at $765.9M across 27 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $237.5M | 31.0% | 6,263,151 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $209.0M | 27.3% | 5,612,896 | Common | SOLE |
| 482929106 | KLRS | KALARIS THERAPEUTICS INC | $66.2M | 8.64% | 11,448,081 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $59.2M | 7.73% | 3,149,128 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $29.8M | 3.89% | 1,717,127 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $19.2M | 2.50% | 4,801,370 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $18.1M | 2.36% | 962,154 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $16.1M | 2.10% | 6,130,268 | Common | SOLE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $16.0M | 2.09% | 343,012 | Common | SOLE |
| 03843E104 | AQST | AQUESTIVE THERAPEUTICS INC | $14.0M | 1.82% | 2,500,000 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $13.1M | 1.72% | 209,634 | Common | SOLE |
| G29687103 | AVDL | AVADEL PHARMACEUTICALS PLC | $10.3M | 1.35% | 675,504 | Common | SOLE |
| 918385204 | VTVT | VTV THERAPEUTICS INC | $8.7M | 1.14% | 374,461 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $7.8M | 1.02% | 3,768,035 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $6.7M | 0.88% | 571,142 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $6.7M | 0.87% | 81,165 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $6.4M | 0.84% | 75,442 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $4.6M | 0.60% | 531,163 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $3.6M | 0.47% | 584,849 | Common | SOLE |
| 98985Y108 | ZYME | ZYMEWORKS INC | $3.6M | 0.46% | 207,901 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $3.1M | 0.41% | 241,400 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $3.1M | 0.40% | 30,285 | Common | SOLE |
| 869367102 | STRO | SUTRO BIOPHARMA INC | $1.9M | 0.25% | 2,196,814 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $1.0M | 0.13% | 135,573 | Common | SOLE |
| 097702203 | BOLT | BOLT BIOTHERAPEUTICS INC | $259,776 | 0.03% | 48,830 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $26,947 | 0.00% | 133,333 | Common | SOLE |
| 86889P117 | SRZNW | SURROZEN INC | $1,780 | 0.00% | 99,999 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.